Pavlikova K. V., Liadova T. I, Popov M. M., Volobuieva O. V., Dorosh D. M., Sanina K. S.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The levels of monocyte-specific chemoattractant-1 in patients with infectious mononucleosis caused by Epstein-Barr virus in moderate to severe disease were studied. Objective: to assess the levels of MCP-1 and the presence of correlations between laboratory and immune parameters in patients with infectious mononucleosis caused by Epstein-Barr virus. Materials and methods. To achieve this goal, 80 patients with MI were examined, including 38 women (47.5%), men – 42 (52.5%). The mean age of patients was 24.3±5.3 years. The material for the study was the serum of patients with WEB infection, which was obtained in the dynamics of the disease. The phenotype of blood lymphocytes was determined by flow laser cytometry on a FACS-Calibur (USA) using monoclonal antibodies. MCP-1 levels were determined using a commercial Elabscience (USA) enzyme-linked immunosorbent assay (ELISA) kit on a Chem Well 2900 analyzer (manufactured by Awareness Technology inc., USA). Discussion of research results. In patients with infectious mononucleosis there was a probable increase in the content of CD3+ , CD4+ , CD8+ , CD16+ , CD20+ , CD25+ , (p<0.05) compared with similar indicators of the control group. The analysis of the obtained results allowed to establish that changes in the system of MCP-1 production were revealed in patients with IM. Thus, the minimum levels of MCP-1 were 7.5 pkg/ml, and the maximum – 161.4 pkg/ml. The median distribution was 39.75 pkg/ml. The average values were 45.5±3.88 pkg/ml, which probably exceeded the control group of patients. The statistical analysis showed the presence of correlations between MCP-1 and CD3+ , CD20+ and CD25+ cells and ALT levels. Thus, between the levels of MCP-1, the presence of moderate correlations between CD3+ (r=+0.53; p˂0.05); CD20+ (r= +0.48; p˂0.05); CD25+ (r=+0.51; p˂0.05) and ALT (r=+0.46; p˂0.05). No statistically significant difference was found between other indicators. The results of the study proved that MCP1-mediated mechanism of involvement of monocytes and macrophages in the infectious process is associated with the course of the disease and its consequences. The progressive nature of changes in immune parameters in MI indicates the formation of secondary cellular immune imbalance, a change in the balance of immunoregulatory mediators in the direction of Th2 cells. In the acute period of MI, probable disorders of the cellular immune system were found, which was characterized by an increase in the number of cells with killer activity: mature T lymphocytes(CD3+ ), cytotoxic T-suppressor cells (CD8+ ), cells expressing the activation marker CD25+ ) and increasing the levels of MCP-1. Conclusions. In patients with IM caused by Epstein-Barr virus in the midst of the disease found an increase in MCP-1 levels compared with the control group. The presence of moderate correlations between CD3+ , CD20+ and CD25+ cells and ALT levels was revealed, which indicates a violation of the cellular immune system and the presence of MCP-1-mediated mechanism of monocyte involvement.

infectious mononucleosis, Epstein-Barr virus, monocyte-specific chemoattractant, immune response.

1. Luzuriaga К, Sullivan JL. Infectious mononucleosis. NEJM. 2010;362(21):1993-2000. DOI: 10.1056/NEJMcp1001116.
2. Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin. Microbiol Rev. 2011;24(1):193-209. DOI: 10.1128/CMR.00044-10.
3. Drozdova NF, Fazulov VKh. Ynfektsyonnyi mononukleoz, obuslovlennyi vyrusom Эpshteina–Barr: klynykopatohenetycheskye aspekty (obzor lyteratury). Vestnyk sovremennoi klynycheskoi medytsyny. 2018;11(3):59-61. Available from: https://cyberleninka.ru/article/n/ infektsionnyy-mononukleoz-obuslovlennyy-virusom-epshteyna-barr-kliniko-patogeneticheskie-aspekty-obzor-literatury. [in Russian].
4. Balfour HHJr, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunol. 2015;4(2):e33. DOI: 10.1038/cti.2015.1.
5. Demyna OY, Chebotareva TA, Mazankova LN, Tetova VB, Uchaeva ON. Klynycheskye proiavlenyia ynfektsyonnoho mononukleoza pry pervychnoi yly reaktyvyrovannoi herpesvyrusnoi ynfektsyy. Rossyiskyi vestnyk perynatolohyy y pedyatryy. 2020;65(1):37-44. DOI: 10.21508/1027-4065-2020-65-1-37-44. [in Russian].
6. Solomai TV, Semenenko TA, Fylatov NN, Kolbutova KB, Oleinykova DIu, Karazhas NV. Rol detei y vzroslykh kak rezervuara vozbudytelei v peryod sezonnoho podiema zabolevaemosty ynfektsyiamy verkhnykh dykhatelnykh putei. Detskye ynfektsyy. 2020;19(3):5-11. DOI: 10.22627/2072-8107-2020-19-3-5-11. [in Russian].
7. Ysakov VA, Arkhypova EY, Ysakov DV. Herpesvyrusnye ynfektsyy cheloveka. SPb.: SpetsLyt; 2013. 13 s. [in Russian].
8. Balfour HH, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J. Infect. Dis. 2013;207:80-88. DOI: 10.1093/ infdis/jis646.
9. Vozianova ZH, Hley AII. Infektsiyniy mononukleoz yak polietiolohichne zakhvoryuvannya. Suchasni infektsiyi. 2004;2:37-41. [in Ukrainian].
10. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The pathogenesis of Epstein-Barr virus persistent infection. Current opinion in virology. 2013;3(3):227-32. DOI: 10.1016/j.coviro.2013.04.005.
11. Popov М, Lyadova Т, Volobuyeva О, Shepileva N, Kozlov А, Sorokina О. Cytokine production peculiarities in different forms of Epstein-Barr virus infection. Georgian Med News. 2017 Feb;263:55-59.
12. Liadova T, Volobueva O, Pavlikova K, Sorokina O, Gololobova O, Kozlov O. Doslіdzhennya dinamіki pokaznikіv іmunnoї vіdpovіdі u khvorikh na іnfektsіinii mononukleoz, viklikanii vіrusom Epshteina-Barr. J. V. N. Karazin Khark. Nat. Univ. 2019;38:39-48. DOI: 10.26565/2313-6693- 2019-38-05. [in Ukrainian].
13. Lyadova TI, Volobueva OV, Shepileva NV, Gololobova OV. Tipy immunnogo otveta pri razlichnykh formakh Ehpshteina-Barr virusnol infektsii. Mezhdunarodnyi meditsinskii zhurnal. 2017;1(23):70-76. Available from: http://dspace.nbuv.gov.ua/bitstream/handle/123456789/ 125655/15-Liadova.pdf?sequence=1. [in Russian]. 
14. Panee J. Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012 Oct;60(1):1-12. DOI: 10.1016/j. cyto.2012.06.018.
15. Bianconi V, Sahebkar A, Atkin SL, Pirro M. The regulation and importance of monocyte chemoattractant protein-1. Curr Opin Hematol. 2018 Jan;25(1):44-51. DOI: 10.1097/MOH.0000000000000389.
16. Fuchs S, Lavi I, Tzang O, Bessler H, Brosh D, Bental T, et al. Intracoronary monocyte chemoattractant protein 1 and vascular endothelial growth factor levels are associated with necrotic core, calcium and fibrous tissue atherosclerotic plaque components: an intracoronary ultrasound radiofrequency study. Cardiology. 2012;123(2):125-32. DOI: 10.1159/ 000342050.
17. Gel’sіns’ka deklaratsіya Vsesvіtn’oi medichnoi asotsіatsіi Etichnі printsipi medichnikh doslіdzhen’ za uchastyu lyudini u yakostі ob’єkta doslіdzhennya [Internet]. 2008 [cited 2017 May 16]. Available from: .

«Bulletin of problems biology and medicine» Issue 4 (162), 2021 year, 159-164 pages, index UDK 616.4-022.7:578.825.13]-076:612.017

10.29254/2077-4214-2021-4-162-159-164